These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 6761807)

  • 41. [Studies on the effect of various substances on platelet function with several methods].
    Bounameaux Y
    Med Welt; 1973 Feb; 24(5):175-6. PubMed ID: 4156387
    [No Abstract]   [Full Text] [Related]  

  • 42. [The effects of ticlopidine on platelet aggregation: study on 13 atherosclerotic patients].
    Lenci R; Galante A; Borzi M; Ariganello M; Sommariva L; Filice A; Cannata D
    Clin Ter; 1983 Feb; 104(3):205-9. PubMed ID: 6861457
    [No Abstract]   [Full Text] [Related]  

  • 43. Dose-dependent inhibition of human platelet aggregation by prasugrel and its interaction with aspirin in healthy subjects.
    Jakubowski JA; Payne CD; Weerakkody GJ; Brandt JT; Farid NA; Li YG; Naganuma H; Lachno DR; Winters KJ
    J Cardiovasc Pharmacol; 2007 Mar; 49(3):167-73. PubMed ID: 17414229
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Migraine or transient ischemic attacks in a patient with essential thrombocythaemia. Treatment with ticlopidine (author's transl)].
    Bousser MG; Conard J; Lecrubier C; Bousser J
    Ann Med Interne (Paris); 1980; 131(2):87-90. PubMed ID: 7396326
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Some characteristics of mouse platelet aggregation and a comparison of the activity of a range of compounds in mouse and human platelet-rich plasma in vitro.
    Nunn B
    Thromb Haemost; 1981 Feb; 45(1):1-5. PubMed ID: 7245119
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Basic considerations on treatment of increased platelet aggregation in diabetic vasculopathic patients.
    Bizzi B; Leone G; Boni P
    Acta Diabetol Lat; 1974; 11(6):437-45. PubMed ID: 4469856
    [No Abstract]   [Full Text] [Related]  

  • 47. Greater inhibition of platelet aggregation and reduced response variability with prasugrel versus clopidogrel: an integrated analysis.
    Weerakkody GJ; Jakubowski JA; Brandt JT; Payne CD; Naganuma H; Winters KJ
    J Cardiovasc Pharmacol Ther; 2007 Sep; 12(3):205-12. PubMed ID: 17875947
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Thromboxane A2, prostacyclin and aspirin: effects on vascular tone and platelet aggregation.
    Smith JB; Araki H; Lefer AM
    Circulation; 1980 Dec; 62(6 Pt 2):V19-25. PubMed ID: 7002350
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of antianginal drugs on platelet aggregation of rabbits.
    Takano S; Anzai T; Ogawa J; Suzuki T
    Fukushima J Med Sci; 1980 Jun; 27(1-2):25-9. PubMed ID: 6800909
    [No Abstract]   [Full Text] [Related]  

  • 50. 2'-Ethoxy-5'-methoxy-2-(5-methylthienyl)chalcone inhibits collagen-induced protein tyrosine phosphorylation and thromboxane formation during platelet aggregation and adhesion.
    Lo HM; Huang TF; Lin CN; Peng HC; Wu WB
    Pharmacology; 2009; 84(3):145-52. PubMed ID: 19690443
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Adenosine-mediated inhibition of platelet aggregation by acadesine. A novel antithrombotic mechanism in vitro and in vivo.
    Bullough DA; Zhang C; Montag A; Mullane KM; Young MA
    J Clin Invest; 1994 Oct; 94(4):1524-32. PubMed ID: 7929829
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Combined administration of 5-HT2 and thromboxane A2 antagonists: effects on platelet aggregation and isolated cardiac muscle.
    Shaw LA; Batey AJ; Coker SJ
    Br J Pharmacol; 1997 Jul; 121(5):875-82. PubMed ID: 9222543
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antiplatelet therapy.
    Sloan RW
    Am Fam Physician; 1981 Oct; 24(4):129-34. PubMed ID: 7025599
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Characterization of biochemical and functional effects of antiplatelet drugs as a key to their clinical development.
    Patrono C; Patrignani P; Rocca B; Landolfi R
    Thromb Haemost; 1995 Jul; 74(1):396-400. PubMed ID: 8578493
    [No Abstract]   [Full Text] [Related]  

  • 55. [Pharmazie in unserer Zeit 4/2009].
    Alban S; Dingermann T
    Pharm Unserer Zeit; 2009; 38(4):295. PubMed ID: 19572344
    [No Abstract]   [Full Text] [Related]  

  • 56. Inhibition of platelet aggregation with prasugrel and clopidogrel: an integrated analysis in 846 subjects.
    Li YG; Ni L; Brandt JT; Small DS; Payne CD; Ernest CS; Rohatagi S; Farid NA; Jakubowski JA; Winters KJ
    Platelets; 2009 Aug; 20(5):316-27. PubMed ID: 19637095
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of physiologic shear stresses and calcium on agonist-induced platelet aggregation, secretion, and thromboxane A2 formation.
    Viisoreanu D; Gear A
    Thromb Res; 2007; 120(6):885-92. PubMed ID: 17306868
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Potentiation of the inhibitory effect of adenosine on platelet aggregation by drugs that prevent its uptake.
    Born GV; Mills DC
    J Physiol; 1969 May; 202(1):41P-42P. PubMed ID: 5770909
    [No Abstract]   [Full Text] [Related]  

  • 59. In vitro study of ticlopidine, as a model of antisickling action of platelet antiaggregant.
    Sablayrolles M; Wajcman H; Castaigne JP; Labie D
    Haematologia (Budap); 1984; 17(2):199-207. PubMed ID: 6534828
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The action of non-steroidal antiinflammatory agents on platelet aggregation and vessel tone in relation to inhibition of PGI2- and thromboxane-release. With particular reference to 5-benzoyl-alpha-methyl-2-thiophene acetic acid (tiaprofenic acid).
    Kuhn A; Sauerland S; Schiffer K; Schrör K
    Arzneimittelforschung; 1980; 30(9):1538-42. PubMed ID: 7006618
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.